Clinical Trial Detail

NCT ID NCT03794544
Title Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedImmune LLC
Indications

lung non-small cell carcinoma

Therapies

Durvalumab + Oleclumab

AZD9150 + Durvalumab

Durvalumab

Durvalumab + Monalizumab

Age Groups: adult senior

No variant requirements are available.